COMPASS Pathways plc
CMPS
$10.96
$1.5916.97%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
5/13/2026
-
MarketBeat
5/13/2026
-
Benzinga
5/13/2026
-
GuruFocus
5/13/2026
-
Seeking Alpha - Healthcare
5/10/2026
-
Simply Wall St
5/6/2026
-
Business Wire
5/6/2026
-
MarketBeat
5/6/2026
-
Business Wire
5/5/2026
-
Simply Wall St
5/4/2026
-
24/7 Wall St.
5/4/2026
-
MarketBeat
5/3/2026
-
TipRanks Financial Blog
5/3/2026
-
Simply Wall St
4/30/2026
-
TipRanks Financial Blog
4/30/2026
-
MarketBeat
4/29/2026
-
Slashdot
4/29/2026
-
MarketBeat
4/28/2026
-
MarketBeat
4/27/2026
-
Market Exclusive
How Investors May Respond To COMPASS Pathways (CMPS) FDA Priority Review Path For Psilocybin Therapy
4/27/2026
-
Simply Wall St
4/27/2026
-
Yahoo! Finance: News
4/27/2026
-
Insider Monkey
4/25/2026
-
TipRanks Financial Blog
4/25/2026
-
Zero Hedge
4/27/2026
-
MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
--
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, March 24, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 4 and 8 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
44 716 6766461
Address
33 Broadwick Street
London, W1F 0DQ
London, W1F 0DQ
Country
Year Founded
Business Description
Sector
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in...
more